Enzon Oncaspar Gains First-Line Leukemia Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
Pegaspargase allows for a more convenient dosing regimen than Merck's Elspar, the current standard of care for acute lymphoblastic leukemia, FDA says.
You may also be interested in...
Enzon Expects First-Line Indication For Oncaspar In Mid-2006
FDA accepts a supplemental BLA for the pediatric acute lymphoblastic leukemia therapy, the firm announces Dec. 1.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.